COMPLETED

Study of DF9001 in Patients With Advanced Solid Tumors

Conditions

Solid Tumor, Adult EGFR NK Cell Immunotherapy Non-Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Renal Cell Carcinoma pembrolizumab KEYTRUDA®

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors (monotherapy and in combination with pembrolizumab).

Official Title

A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF9001 as a Monotherapy and in Combination Therapies in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications

Quick Facts

Study Start:2022-11-15

Study Completion:2025-08-15

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT05597839

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Signed written informed consent. 2. Male or female patients aged ≥ 18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months. 4. Adequate hematological function per protocol. 5. Adequate hepatic function per protocol. 6. Adequate renal function per protocol. 7. Participation in the use of contraception during the study, and for 150 days after the last dose of study drug for women of child-bearing potential (WOCBP) and 30 days after the last dose of study drug for male patients, as defined by the Clinical Trial Facilitation Group (CTFG) guidelines.	1. Patients must not have had chemotherapy, radiotherapy (other than palliative bone- directed radiotherapy, as described in in exclusion criterion #2), or major surgery, or received another investigational agent within 28 days or 5 half-lives of the drug (if known), whichever is shorter, before the start of study treatment. 2. Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids. 3. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention. 4. Concurrent anticancer treatment (eg, cytoreductive therapy, radiotherapy \[except for palliative bone-directed radiotherapy, which is not a target lesion\], immune therapy, or cytokine therapy \[except for erythropoietin\]), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days or 5 half-lives of the drug (if known), whichever is shorter, before the start of study treatment. Short-term administration of systemic steroids (eg, for allergic reactions or the management of irAEs) is allowed. Note: Patients receiving bisphosphonate or denosumab are eligible, provided treatment was initiated at least 14 days before the first dose of DF9001. 5. Previous malignant disease other than the target malignancy to be investigated in this study within the last 3 years. Exceptions (eg, basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ) can be considered on a case-by-case basis, in consultation with the Medical Monitor. 6. Life expectancy of less than 6 months. 7. Receipt of any organ transplantation, including autologous or allogeneic stem-cell transplantation. 8. Significant acute or chronic infections (including historic positive test for human immunodeficiency virus \[HIV\], or active or latent hepatitis B or active hepatitis C tested during the screening window). If HBsAg is negative and the anti-hepatitis B core antibody is positive, then hepatitis B viral DNA load must be undetectable. 9. Preexisting autoimmune disease (except for patients with vitiligo) needing treatment with systemic immunosuppressive agents for more than 28 days within the last 3 years, or clinically relevant immunodeficiencies (eg, dysgammaglobulinemia or congenital immunodeficiencies). Patients with a history of immune-related endocrinopathies (eg, hypothyroidism, type 1 diabetes mellitus \[TIDM\], and adrenal insufficiency) that are stable on hormone replacement therapy may be eligible for this study. 10. Patients with a known medical history that may place them at risk of known toxicities of EGFR blockade. 1. History of or ongoing keratitis, ulcerative keratitis, or corneal perforation. 2. History of cardiopulmonary arrest unless this was caused by an acute, reversible etiology that is no longer present. 3. History of or ongoing pulmonary fibrosis or interstitial lung disease. 11. Known severe hypersensitivity reactions to mAbs (≥ Grade 3 of the NCI-CTCAE v5.0), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partly controlled asthma). 12. Persisting toxicity related to prior therapy \>Grade 1 NCI-CTCAE v5.0; however, alopecia ≤Grade 2, endocrinopathies ≤Grade 2, and sensory neuropathy ≤ Grade 2 is acceptable. 13. Patients who have received an anti-PD-(L)1 as a previous line of therapy that have experienced either of the following: 1. a Grade 3 or Grade 4 drug-related toxicity. 2. a Grade 2 drug-related toxicity that impacted either the lungs, cardiac, or the nervous system, caused by the administration of the anti-PD-(L)1. 14. Received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis. 15. A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 16. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Administration of killed vaccines are allowed. 17. Pregnancy or lactation in females during the study. 18. Known alcohol or drug abuse. 19. Serious cardiac illness or medical conditions, including but not limited to: 1. History of New York Heart Association class III or IV heart failure or systolic dysfunction (left ventricular ejection fraction \[LVEF\] \<55%). 2. High-risk uncontrolled arrhythmias (eg, tachycardia with a heart rate \>100/min at rest). 3. Significant ventricular arrhythmia (ventricular tachycardia) or higher-grade atrioventricular (AV) block (eg, AV-block, second degree AV block Type 2 \[Mobitz 2\], or third-degree AV-block). 4. Angina pectoris requiring anti-anginal medication. 5. Clinically significant valvular heart disease. 6. Evidence of transmural infarction on electrocardiograms (ECGs). 7. Poorly controlled hypertension (defined as systolic \>160 mm Hg or diastolic \>100 mm Hg). 8. Clinically relevant uncontrolled cardiac risk factors, clinically relevant pulmonary disease, or any clinically relevant medical condition in the opinion of the Investigator that may limit participation in this study. 9. Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy. 20. All other significant diseases (eg, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the patient's ability to participate. 21. Any psychiatric condition that would prohibit the understanding or rendering of informed consent. 22. Legal incapacity or limited legal capacity. 23. Incapable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. 24. Has received radiation therapy to the lung that is \>30 Gy within 6 months of the first dose of study treatment (for NSCLC cohorts only). 25. Patients with brain metastases, unless all of the following criteria are met: 1. CNS lesions are asymptomatic, previously treated and no active therapy is required (ie, no corticosteroids for edema), 2. Radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study intervention. 3. Imaging demonstrates stability of disease 28 days from last treatment for CNS metastases. 26. Active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid). 27. Patients with leptomeningeal disease are excluded. 28. History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. 29. Active infection requiring systemic therapy. 30. Severe hypersensitivity (≥Grade 3) to pembrolizumab, and/or any of its excipients.

Inclusion Criteria

Exclusion Criteria

1. Signed written informed consent.
2. Male or female patients aged ≥ 18 years.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months.
4. Adequate hematological function per protocol.
5. Adequate hepatic function per protocol.
6. Adequate renal function per protocol.
7. Participation in the use of contraception during the study, and for 150 days after the last dose of study drug for women of child-bearing potential (WOCBP) and 30 days after the last dose of study drug for male patients, as defined by the Clinical Trial Facilitation Group (CTFG) guidelines.

1. Patients must not have had chemotherapy, radiotherapy (other than palliative bone- directed radiotherapy, as described in in exclusion criterion #2), or major surgery, or received another investigational agent within 28 days or 5 half-lives of the drug (if known), whichever is shorter, before the start of study treatment.
2. Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids.
3. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
4. Concurrent anticancer treatment (eg, cytoreductive therapy, radiotherapy \[except for palliative bone-directed radiotherapy, which is not a target lesion\], immune therapy, or cytokine therapy \[except for erythropoietin\]), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days or 5 half-lives of the drug (if known), whichever is shorter, before the start of study treatment. Short-term administration of systemic steroids (eg, for allergic reactions or the management of irAEs) is allowed. Note: Patients receiving bisphosphonate or denosumab are eligible, provided treatment was initiated at least 14 days before the first dose of DF9001.
5. Previous malignant disease other than the target malignancy to be investigated in this study within the last 3 years. Exceptions (eg, basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ) can be considered on a case-by-case basis, in consultation with the Medical Monitor.
6. Life expectancy of less than 6 months.
7. Receipt of any organ transplantation, including autologous or allogeneic stem-cell transplantation.
8. Significant acute or chronic infections (including historic positive test for human immunodeficiency virus \[HIV\], or active or latent hepatitis B or active hepatitis C tested during the screening window). If HBsAg is negative and the anti-hepatitis B core antibody is positive, then hepatitis B viral DNA load must be undetectable.
9. Preexisting autoimmune disease (except for patients with vitiligo) needing treatment with systemic immunosuppressive agents for more than 28 days within the last 3 years, or clinically relevant immunodeficiencies (eg, dysgammaglobulinemia or congenital immunodeficiencies). Patients with a history of immune-related endocrinopathies (eg, hypothyroidism, type 1 diabetes mellitus \[TIDM\], and adrenal insufficiency) that are stable on hormone replacement therapy may be eligible for this study.
10. Patients with a known medical history that may place them at risk of known toxicities of EGFR blockade.
1. History of or ongoing keratitis, ulcerative keratitis, or corneal perforation.
2. History of cardiopulmonary arrest unless this was caused by an acute, reversible etiology that is no longer present.
3. History of or ongoing pulmonary fibrosis or interstitial lung disease.
11. Known severe hypersensitivity reactions to mAbs (≥ Grade 3 of the NCI-CTCAE v5.0), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partly controlled asthma).
12. Persisting toxicity related to prior therapy \>Grade 1 NCI-CTCAE v5.0; however, alopecia ≤Grade 2, endocrinopathies ≤Grade 2, and sensory neuropathy ≤ Grade 2 is acceptable.
13. Patients who have received an anti-PD-(L)1 as a previous line of therapy that have experienced either of the following:
1. a Grade 3 or Grade 4 drug-related toxicity.
2. a Grade 2 drug-related toxicity that impacted either the lungs, cardiac, or the nervous system, caused by the administration of the anti-PD-(L)1.
14. Received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis.
15. A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
16. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Administration of killed vaccines are allowed.
17. Pregnancy or lactation in females during the study.
18. Known alcohol or drug abuse.
19. Serious cardiac illness or medical conditions, including but not limited to:
1. History of New York Heart Association class III or IV heart failure or systolic dysfunction (left ventricular ejection fraction \[LVEF\] \<55%).
2. High-risk uncontrolled arrhythmias (eg, tachycardia with a heart rate \>100/min at rest).
3. Significant ventricular arrhythmia (ventricular tachycardia) or higher-grade atrioventricular (AV) block (eg, AV-block, second degree AV block Type 2 \[Mobitz 2\], or third-degree AV-block).
4. Angina pectoris requiring anti-anginal medication.
5. Clinically significant valvular heart disease.
6. Evidence of transmural infarction on electrocardiograms (ECGs).
7. Poorly controlled hypertension (defined as systolic \>160 mm Hg or diastolic \>100 mm Hg).
8. Clinically relevant uncontrolled cardiac risk factors, clinically relevant pulmonary disease, or any clinically relevant medical condition in the opinion of the Investigator that may limit participation in this study.
9. Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.
20. All other significant diseases (eg, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the patient's ability to participate.
21. Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
22. Legal incapacity or limited legal capacity.
23. Incapable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
24. Has received radiation therapy to the lung that is \>30 Gy within 6 months of the first dose of study treatment (for NSCLC cohorts only).
25. Patients with brain metastases, unless all of the following criteria are met:
1. CNS lesions are asymptomatic, previously treated and no active therapy is required (ie, no corticosteroids for edema),
2. Radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study intervention.
3. Imaging demonstrates stability of disease 28 days from last treatment for CNS metastases.
26. Active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid).
27. Patients with leptomeningeal disease are excluded.
28. History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
29. Active infection requiring systemic therapy.
30. Severe hypersensitivity (≥Grade 3) to pembrolizumab, and/or any of its excipients.

Contacts and Locations

Study Locations (Sites)

Banner MD Anderson

Gilbert, Arizona, 85234

United States

Mayo Clinic Arizona

Phoenix, Arizona, 85054

United States

UC Irvine Medical Center

Irvine, California, 92617

United States

USC/Norris Comprehensive Cancer Center

Los Angeles, California, 90033

United States

Mayo Clinic Jacksonville

Jacksonville, Florida, 32224

United States

University of Louisville Hospital

Louisville, Kentucky, 40202

United States

Mayo Clinic Minnesota

Rochester, Minnesota, 55905

United States

AMR Kansas City

Kansas City, Missouri, 64114

United States

Rutgers

New Brunswick, New Jersey, 08903

United States

Icahn School of Medicine at Mount Sinai

New York, New York, 10029

United States

University of Cincinnati

Cincinnati, Ohio, 45219

United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111

United States

UMPC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232

United States

Rhode Island Hospital

Providence, Rhode Island, 02903

United States

Medical University of South Carolina

Charleston, South Carolina, 29425

United States

Virginia Cancer Specialists

Fairfax, Virginia, 22031

United States

University of Wisconsin

Madison, Wisconsin, 53792

United States

Collaborators and Investigators

Sponsor: Dragonfly Therapeutics

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-15

Study Completion Date2025-08-15

Study Record Updates

Study Start Date2022-11-15

Study Completion Date2025-08-15

Terms related to this study

Keywords Provided by Researchers

EGFR
NK Cell
Immunotherapy
Non-Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
pembrolizumab
KEYTRUDA®

Additional Relevant MeSH Terms

Solid Tumor, Adult